Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Article in English | MEDLINE | ID: mdl-22654229

ABSTRACT

This study was conducted to find out the frequency of complementary and alternative medicine (CAM) use that could lead to troubles in patient health and in applied standard therapy protocols when used improperly, which method is used, the reasons for use and from which resources the information about this topic were obtained. A questionnaire consisting of 28 questions was applied to 195 patients with cancer diagnosis by a face-to-face interview. The obtained data were assessed with SPSS 11.5 program. Out of 195 cancer patients, 100 (51.3%) were using CAM and 48.7% (n=95) were not. The most commonly used agent was nettle (72%). This was followed by herbal teas (21%), grape molasses (20%) and black seed (20%). The frequency of CAM use was found higher in those under age 50, in literate people, in those working during the diagnosis stage and having disease at the later stage. While CAM was commonly recommended by friends and relatives of the patients (73%), this ratio was only 5% for health professionals. While 51.3% of all patients were gathering information about CAM, 75% of those actually using CAM gathered information about it. Whilst information was gathered mostly from the relatives of patients and tamperers (47%), it can be gathered from physicians only with a ratio of 10%. Cancer patients use CAM and they gather information mainly from unreliable sources rather than physicians. Although the primary information source should be physicians, the ratio for this was very low (10%). We suggest that physicians should spend more time in gathering correct information and sharing them with their patients for a better guidance.


Subject(s)
Complementary Therapies/statistics & numerical data , Health Knowledge, Attitudes, Practice , Neoplasms/therapy , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Female , Humans , Interviews as Topic , Male , Middle Aged , Prevalence , Socioeconomic Factors , Surveys and Questionnaires , Turkey , Young Adult
2.
Int J Radiat Oncol Biol Phys ; 72(5): 1530-7, 2008 Dec 01.
Article in English | MEDLINE | ID: mdl-18707825

ABSTRACT

PURPOSE: To determine the patterns of care for lung cancer in Turkish radiation oncology centers. METHODS AND MATERIALS: Questionnaire forms from 21 of 24 (87.5%) centers that responded were evaluated. RESULTS: The most frequent histology was non-small cell lung cancer (NSCLC) (81%). The most common postoperative radiotherapy (RT) indications were close/(+) surgical margins (95%) and presence of pN2 disease (91%). The most common indications for postoperative chemotherapy (CHT) were ">/= IB" disease (19%) and the presence of pN2 disease (19%). In Stage IIIA potentially resectable NSCLC, the most frequent treatment approach was neoadjuvant concomitant chemoradiotherapy (CHRT) (57%). In Stage IIIA unresectable and Stage IIIB disease, the most frequent approach was definitive concomitant CHRT (91%). In limited SCLC, the most common treatment approach was concomitant CHRT with cisplatin+etoposide for cycles 1-3, completion of CHT to cycles 4-6, and finally prophylactic cranial irradiation in patients with complete response (71%). Six cycles of cisplatin + etoposide CHT and palliative thoracic RT, when required, was the most commonly used treatment (81%) in extensive SCLC. Sixty-two percent of centers did not have endobronchial brachytherapy (EBB) facilities. CONCLUSION: There is great variation in diagnostic testing, treatment strategies, indications for postoperative RT and CHT, RT features, and EBB availability for LC cases. To establish standards, national guidelines should be prepared using a multidisciplinary approach.


Subject(s)
Lung Neoplasms/radiotherapy , Patient Care/methods , Brachytherapy/statistics & numerical data , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/pathology , Carcinoma, Non-Small-Cell Lung/radiotherapy , Carcinoma, Non-Small-Cell Lung/surgery , Combined Modality Therapy , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Neoplasm Staging , Patient Care/statistics & numerical data , Radiation Oncology/organization & administration , Radiation Oncology/statistics & numerical data , Radiotherapy Dosage , Risk Assessment , Small Cell Lung Carcinoma/pathology , Small Cell Lung Carcinoma/radiotherapy , Small Cell Lung Carcinoma/surgery , Surveys and Questionnaires , Turkey , Workforce
3.
Am J Hematol ; 83(9): 702-7, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18543343

ABSTRACT

To identify the outcomes of prognostic factors of solitary plasmacytoma mainly treated with local radiotherapy (RT). The data were collected from 80 patients with solitary plasmacytoma (SP). Forty patients (50.0%) received radiotherapy (RT) alone while 38 of them (47.5%) were treated with surgery (S) and RT. The median radiation dose was 46 Gy (range 30-64). The median follow up was 2.41 years (range 0.33-12.33). Ten-year overall survival (OS) and local relapse-free survival (LRFS) were 73% and 94%, respectively. The median progression-free survival (PFS) and multiple myeloma-free survival (MMFS) were 3.5 years and 4.8 years, respectively. On multivariate analyses, the favorable factors were radiotherapy dose of > or =50 Gy and RT + S for PFS and younger age for MMFS. For the patients with medullary plasmacytoma, the favorable factor was younger age for MMFS. RT at > or =50 Gy and RT + S may be favorable prognostic factors on PFS. Younger patients, especially with head-neck lesion and without pre-RT macroscopic tumor, seem to have the best outcome when treated with RT +/- S. Progression to MM remains as the main problem especially for older patients.


Subject(s)
Plasmacytoma/radiotherapy , Adolescent , Adult , Aged , Bone Neoplasms/mortality , Bone Neoplasms/radiotherapy , Bone Neoplasms/surgery , Combined Modality Therapy , Disease Progression , Disease-Free Survival , Female , Follow-Up Studies , Humans , Male , Middle Aged , Multiple Myeloma/diagnosis , Multiple Myeloma/epidemiology , Plasmacytoma/mortality , Plasmacytoma/surgery , Prognosis , Radiotherapy Dosage , Risk , Survival Analysis , Treatment Outcome , Turkey/epidemiology
4.
Med Oncol ; 25(3): 269-73, 2008.
Article in English | MEDLINE | ID: mdl-18080790

ABSTRACT

The aim of the study was to evaluate the toxicity and efficacy of 62 patients with locally advanced nasopharyngeal carcinoma (NPC) (stage III, IVA, IVB) treated by three different modalities. Cisplatin was given weekly 35 mg/m(2)/day or every 3 weeks 100 mg/m(2)/day during radiotherapy (RT) in all patients. Patients were classified into following three groups: The patients in the group 1 (n=23) were treated only with concurrent chemoradiotherapy (CCRT). In the group 2 (n=15), before the CCRT, neoadjuvant chemotherapy, consisting of intravenous cisplatin and docetaxel on day 1, every 3 weeks treatment cycles was administered. In the group 3 (n=24), adjuvant chemotherapy, consisting of cisplatin on day 1 and 5-fluorouracil on day 1 to 5 every 3 weeks was used after CCRT. Three arms were treated with the same RT technique and dose. There was no difference for age, sex, and stage among the groups. Radiotherapy was administered in planned dose for all patients. A total of 82% patients completed planned chemotherapy concurrent with RT. The treatment related adverse effects were mild or moderate in intensity. There was no statistical difference between the groups regarding the treatment responses. Complete response rate of RT was 73.9%, 86.7%, and 87.5%, respectively. Median progression free survival (PFS) and overall survival (OS) were 13, 12, 9 months and 22, 20, 15 months for groups 1, 2, 3, respectively. No difference was observed in median OS and PFS among three groups. In our study, the efficacy and toxicity of neoadjuvant and/or adjuvant chemotherapy with CCRT and CCRT alone were found similar.


Subject(s)
Nasopharyngeal Neoplasms/drug therapy , Nasopharyngeal Neoplasms/radiotherapy , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Chemotherapy, Adjuvant/adverse effects , Cisplatin/adverse effects , Cisplatin/therapeutic use , Combined Modality Therapy , Disease Progression , Docetaxel , Female , Fluorouracil/adverse effects , Fluorouracil/therapeutic use , Humans , Male , Middle Aged , Nasopharyngeal Neoplasms/pathology , Neoadjuvant Therapy/adverse effects , Neoplasm Staging , Radiotherapy, Adjuvant/adverse effects , Retrospective Studies , Taxoids/adverse effects , Taxoids/therapeutic use , Young Adult
5.
Eur Surg Res ; 39(3): 141-7, 2007.
Article in English | MEDLINE | ID: mdl-17337891

ABSTRACT

BACKGROUND: Preoperative radiotherapy (RT) is an increasingly popular form of adjunct therapy for rectal cancer; however, little is known about its effects on matrix metalloproteinase (MMP) expression in colonic anastomotic healing. METHODS: Wistar rats were irradiated to a total dose of 25 or 40 Gy. Four days after the end of RT, an end-to-end colorectal anastomosis was performed. Animals were sacrificed at 1, 3, and 7 days after the anastomosis. A control group was studied similarly, but was not irradiated. RESULTS: No significant differences were found in peritonitis rate and anastomotic complications. The average bursting pressure and breaking strength were only reduced significantly in the rats irradiated with 40 Gy. However, the concentration and the content of hydroxyproline in anastomotic tissues were unchanged. In irradiated rats, MMP-2 and MMP-9 were significantly increased at 40 Gy, but not at 25 Gy. On the other hand, 25-Gy irradiation induced a smaller increase in the levels of the tissue inhibitors of metalloproteinase-1 compared with the controls. CONCLUSION: Anastomotic strength is adversely affected by high-dose fractionated preoperative RT. In contrast, preoperative RT at 25 Gy in five fractions over 5 days is safe with regard to the maintenance of wound strength in colorectal anastomosis.


Subject(s)
Colon/surgery , Matrix Metalloproteinase 2/radiation effects , Matrix Metalloproteinase 9/radiation effects , Rectal Neoplasms/radiotherapy , Wound Healing/radiation effects , Anastomosis, Surgical , Animals , Biomechanical Phenomena , Hydroxyproline/radiation effects , Male , Preoperative Care , Radiotherapy Dosage , Radiotherapy, Adjuvant/methods , Rats , Rats, Wistar , Rectal Neoplasms/surgery , Tissue Inhibitor of Metalloproteinase-1/radiation effects
6.
Int J Radiat Oncol Biol Phys ; 67(1): 196-203, 2007 Jan 01.
Article in English | MEDLINE | ID: mdl-17071013

ABSTRACT

PURPOSE: To analyze whether the expression of matrix metalloproteinases (MMPs) and their tissue inhibitors are associated with tumor response to preoperative chemoradiotherapy in rectal cancer patients. METHODS AND MATERIALS: Forty-four patients who had undergone preoperative chemoradiotherapy were evaluated retrospectively. Treatment consisted of pelvic radiotherapy and two cycles of 5-fluorouracil plus leucovorin. Surgery was performed 6-8 weeks later. MMP-2, MMP-9, and tissue inhibitors of metalloproteinase-1 and -2 expression was analyzed by immunohistochemistry of the preradiation biopsy and surgical specimens. The intensity and extent of staining were evaluated separately, and a final score was calculated by multiplying the two scores. The primary endpoint was the correlation of expression with tumor response, with the secondary endpoint the effect of chemoradiotherapy on the expression. RESULTS: Preoperative treatment resulted in downstaging in 20 patients (45%) and no clinical response in 24 (55%). The pathologic tumor response was complete in 11 patients (25%), partial in 23 (52%), and none in 10 (23%). Positive MMP-9 staining was observed in 20 tumors (45%) and was associated with the clinical nodal stage (p = 0.035) and the pathologic and clinical response (p < 0.0001). The staining status of the other markers was associated with neither stage nor response. The overall pathologic response rate was 25% in MMP-9-positive patients vs. 52% in MMP-9-negative patients (p = 0.001). None of the 11 patients with pathologic complete remission was MMP-9 positive. CONCLUSIONS: Matrix metalloproteinase-9 expression correlated with a poor tumor response to preoperative chemoradiotherapy in rectal carcinoma patients.


Subject(s)
Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 9/analysis , Neoplasm Proteins/analysis , Rectal Neoplasms/chemistry , Tissue Inhibitor of Metalloproteinase-1/analysis , Tissue Inhibitor of Metalloproteinase-2/analysis , Adult , Aged , Aged, 80 and over , Antimetabolites, Antineoplastic/therapeutic use , Combined Modality Therapy/methods , Female , Fluorouracil/therapeutic use , Humans , Leucovorin/therapeutic use , Logistic Models , Male , Middle Aged , Neoplasm Staging , Rectal Neoplasms/drug therapy , Rectal Neoplasms/pathology , Rectal Neoplasms/radiotherapy , Retrospective Studies
7.
Am J Clin Oncol ; 29(2): 183-8, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16601440

ABSTRACT

OBJECTIVES: The purpose of the present study was to evaluate the nutritional status of cancer patients receiving radiotherapy (RT) and to assess the possible contributions of nutritional support to patients with malnutrition. METHODS: Prospectively, 207 patients referred to our outpatient radiotherapy department were included. The patients were classified according to tumor site (head/neck, breast, lung, stomach, or colorectal). Nutritional status at the onset, at the end of RT, and 3 and 6 months after irradiation was evaluated with the subjective global assessment (SGA). All of the patients were supported with additional portions of meal or standard enteral feeding formula during and after the irradiation period as long as they were in the moderately or severely malnourished groups, respectively. RESULTS: At the onset, malnutrition was present in 31% of all patients, and it increased to 43% at the end of RT. This difference predominated in head/neck cancer patients. Malnutrition ratios in head/neck cancer patients at the onset and after RT were 24% and 88%, respectively. By a 6-month follow-up, the ratio of patients with malnutrition decreased to 8%. Nutritional status of all groups was found to improve during the 6-month follow-up period, except for the breast cancer group, which included no patients with severe malnutrition at any time. CONCLUSION: The results of the present study may be helpful in planning an appropriate nutritional support for cancer patients undergoing radiotherapy according to the irradiation site.


Subject(s)
Neoplasms/radiotherapy , Nutritional Status , Nutritional Support , Adolescent , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Malnutrition/etiology , Middle Aged , Outpatients , Prospective Studies
8.
Radiother Oncol ; 77(3): 262-6, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16298000

ABSTRACT

PURPOSE: The aim of this study was to investigate the effects of tangential radiotherapy (RT) on lung clearance in the patients with breast cancer by using (99m)Tc-DTPA aerosol scintigraphy. MATERIAL AND METHODS: Thirty-three female patients [non-smoker: 20, ex-smoker: 13] performed surgery and systemic chemotherapy for breast carcinoma [47+/-13 years] were included in the study. All patients underwent (99m)Tc-DTPA aerosol scintigraphy prior to RT (pre RT), midway through RT (mid RT) and after RT (post RT). Total dose was 50 Gy in modified radical mastectomy and 60 Gy in lumpectomy (2 Gy/fraction). Posterior dynamic images of lungs were obtained immediately after the inhalation of (99m)Tc-DTPA aerosol. RESULTS: Pulmonary function tests were normal in three measurements for all cases. In the ex-smokers, there was no significant difference among pre RT, mid RT and post RT clearance values in both lungs. Pre RT lung clearance in non-smoker group did not differ from that in ex-smokers. However, the lung clearance for non-smoker group showed significantly increase following RT. CONCLUSION: In this study, we observed that tangential radiotherapy caused an increase in the lung clearance in the cases of non-smokers even in non-irradiated lung, and that the effect of RT on lung clearance was closely depended on smoking habit before RT.


Subject(s)
Breast Neoplasms/radiotherapy , Lung/diagnostic imaging , Radiation Pneumonitis/prevention & control , Radiotherapy, Conformal , Adult , Aerosols , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/surgery , Female , Humans , Lung/radiation effects , Mastectomy, Modified Radical , Mastectomy, Segmental , Middle Aged , Radiation Pneumonitis/etiology , Radionuclide Imaging , Radiopharmaceuticals , Radiotherapy, Adjuvant , Respiratory Function Tests , Smoking , Tamoxifen/therapeutic use , Technetium Tc 99m Pentetate
9.
Tohoku J Exp Med ; 202(4): 255-63, 2004 Apr.
Article in English | MEDLINE | ID: mdl-15109123

ABSTRACT

The aim of this study is to evaluate the incidence of interstitial pneumonitis following fractionated total body irradiation conditioning for bone marrow transplantation with varying lung doses due to shielding technique and different dose-rates. Between 1987 and 2001, a total number of 105 patients have received total body irradiation conditioning for bone marrow transplantation for hematological malignancies at Gulhane Military Medical School. Twelve Gy fractionated total body irradiation was delivered in 6 fractions over 3 consecutive days with Co-60 teletherapy machine. Conditioning therapy included only cyclophosphamide (60 mg/ kg/day for two days) and total body irradiation. The median follow-up for patients was 12 months. Interstitial pneumonitis developed in 10 patients out of 105 patients (9.52%). The median total dose to lung was 9.60 Gy (8.88-10.90). The difference between total lung dose and interstitial pneumonitis was not significant. Pneumonitis development in the high dose-rate (>0.04 Gy/min) group versus low dose-rate (< or =0.04 Gy/min) group was statistically significant. Low dose-rate fractionated total body irradiation is a reliable conditioning program in bone marrow transplantation with effective lung sparing to avoid interstitial pneumonitis.


Subject(s)
Bone Marrow Transplantation/adverse effects , Lung Diseases, Interstitial/etiology , Transplantation Conditioning/adverse effects , Whole-Body Irradiation/adverse effects , Adolescent , Adult , Bone Marrow Transplantation/methods , Dose-Response Relationship, Radiation , Female , Humans , Leukemia/therapy , Lung/radiation effects , Lung Injury , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Multiple Myeloma/therapy , Radiation Injuries/etiology , Radiation Protection , Retrospective Studies , Transplantation Conditioning/methods , Whole-Body Irradiation/methods
10.
Int J Urol ; 10(8): 435-8, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12887365

ABSTRACT

BACKGROUND: Standard post-orchiectomy radiotherapy (RT) is accepted as a standard management option for stage I seminoma. METHODS: Retrospective evaluation of 74 patients with stage I seminoma was performed according to the Royal Marsden staging system. All of the patients underwent RT in the Radiation Oncology Department of Gülhane Military Medical Academy between 1974 and 1995. The median age of patients was 27 years (range, 20-56). Radiotherapy was applied to all of the patients after orchiectomy for adjuvant purposes. Sixty-nine patients underwent RT while five patients who had recurrence received chemotherapy following radiotherapy. RESULTS: After a mean follow-up period of 54 months, the 5-year overall survival rate was 98.61%, which complied with the literature. The disease-free survival rate was 90.54%. According to the World Health Organization toxicity scale, acute enteritis was 9.4% for grade I and 5.4% for grade II, while nausea/vomiting was 36.4% for grade I and 5.4% for grade II. CONCLUSION: To avoid acute toxicity related to RT, prognostic risk factors should be well-known and patients with low risk factors should be monitored carefully after orchiectomy. RT should be directed to the para-aortic +/- ipsilateral pelvic lymph nodes in high risk patients. Although post-orchiectomy RT is a traditional management option for clinical stage I seminoma, the results of RT should be well-known to compare it with other treatment options (e.g. RPLND, adjuvant chemotherapy and surveillance).


Subject(s)
Seminoma/radiotherapy , Testicular Neoplasms/radiotherapy , Adult , Enteritis/etiology , Follow-Up Studies , Humans , Male , Middle Aged , Nausea/etiology , Orchiectomy , Outcome and Process Assessment, Health Care , Radiotherapy, Adjuvant/adverse effects , Retrospective Studies , Seminoma/mortality , Seminoma/surgery , Survival Rate , Testicular Neoplasms/mortality , Testicular Neoplasms/surgery , Turkey/epidemiology , Vomiting/etiology
11.
J Cancer Res Clin Oncol ; 129(1): 52-6, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12618901

ABSTRACT

PURPOSE: In this study our objective was to evaluate the therapeutic significance of concurrent paclitaxel and radiotherapy compared with radiotherapy alone. PATIENTS AND METHODS: Patients with stage III A/B NSCLC were randomly assigned to receive either radiotherapy alone (group 2) or concurrent weekly paclitaxel with radiotherapy (group 1) in GMMA. Radiotherapy was given as a split-course schedule with the total dose of 56 Gy. Paclitaxel, 60 mg/m(2), was administered only to group 1 on the first day of each radiotherapy week. To assess differences between values, P values were calculated with the chi(2) test. A Mann Whitney U-test was used to assess significant differences between the two values. Actuarial survival curves were calculated by the Kaplan-Meier method. RESULTS: There were 25 patients who underwent chemoradiotherapy and 26 who underwent radiotherapy only. Median follow-up was 14 months. The overall response rate was 92% and 70% for groups 1 and 2, respectively ( P= 0.003). Median survival was 15.2 months for group 1, and 12.0 months for group 2 ( P= 0.027). CONCLUSION: Based on this response and the toxicity profile, outpatient split-course radiotherapy and weekly paclitaxel seems to be feasible and safe.


Subject(s)
Antineoplastic Agents, Phytogenic/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/radiotherapy , Lung Neoplasms/drug therapy , Lung Neoplasms/radiotherapy , Paclitaxel/therapeutic use , Adult , Aged , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/adverse effects , Carcinoma, Non-Small-Cell Lung/pathology , Chemotherapy, Adjuvant/adverse effects , Disease-Free Survival , Drug Administration Schedule , Female , Humans , Lung Neoplasms/pathology , Male , Middle Aged , Paclitaxel/administration & dosage , Paclitaxel/adverse effects , Radiotherapy, Adjuvant/adverse effects , Survival Analysis , Treatment Outcome
12.
Tumori ; 88(4): 277-80, 2002.
Article in English | MEDLINE | ID: mdl-12400976

ABSTRACT

BACKGROUND: The primary aim of the study was to compare two different dose levels of megestrol acetate, administered for cancer-related anorexia and cachexia for 3 months. METHODS: From August 1996 to December 2000, 119 patients with advanced non-small cell lung cancer were randomized to take 160 mg/day or 320 mg/day of megestrol acetate for 3 months at the Gülhane Military Medicine Academy of Ankara, Turkey. Patients were controlled at biweekly periods. RESULTS: There were 59 patients in the single dose arm (group 1) and 60 patients in the twice a day dose arm (group 2). The mean percentages of weight loss were 16.9% and 16.7% in group 1 and 2, respectively. In the first and the second month of weight gain, there were no significant differences in the two groups (P = 0.23 and P = 0.11). In the third month, weight gain was significantly higher in group 2 than in group 1 (P = 0.038). Toxicity was similar for both dose levels. CONCLUSIONS: Megestrol acetate can be safely and effectively given to patients with advanced non-small cell lung cancer. Although lower doses of megestrol acetate can be effective for anorexia and cachexia, the higher dose level seems to be more efficient.


Subject(s)
Anorexia/drug therapy , Cachexia/drug therapy , Carcinoma, Non-Small-Cell Lung/drug therapy , Lung Neoplasms/drug therapy , Megestrol Acetate/administration & dosage , Adult , Aged , Female , Humans , Male , Middle Aged , Weight Gain
13.
Haematologia (Budap) ; 32(1): 25-30, 2002.
Article in English | MEDLINE | ID: mdl-12243552

ABSTRACT

PURPOSE: To assess dose rate effect on cataractogenesis in allogeneic or autologous bone marrow transplanted patients conditioned with fractionated total-body irradiation (FTBI). MATERIALS AND METHODS: Between 1987 and 2001, a total of 105 patients have received TBI conditioning for Bone Marrow Transplantation (BMT) for hematological malignancies at Gulhane Military Medical School. 12 Gy FTBI was applied in 6 fractions over 3 consecutive days with a Co60 teletherapy machine. 46 patients who have survived and were followed up after more than one year were evaluated for cataractogenesis in relation to dose rate. Conditioning therapy included only cyclophosphamide (60 mg/kg/day for two days) + TBI with no steroid and veno-occlusive disease prophylaxis. RESULTS: The median follow-up is 32 months. Posterior subcapsular cataract developed in 5 eyes of three patients out of 46 patients. The 5-year and 10-year estimated cataract incidence in the high-dose rate (> 0.04 Gy/min) group was 29% and 43% respectively while no cataracts occurred in the low-dose rate (< or = 0.04 Gy/min) group. Cataract development in the high-dose rate group versus low-dose rate group was statistically significant (p < 0.039). CONCLUSION: Cataract is a late side effect of TBI. Low-dose rate fractionated TBI is a reliable conditioning program in BMT with effective lens sparing to avoid cataractogenesis.


Subject(s)
Bone Marrow Transplantation/methods , Cataract/etiology , Whole-Body Irradiation/adverse effects , Adolescent , Adult , Bone Marrow Transplantation/adverse effects , Dose Fractionation, Radiation , Dose-Response Relationship, Radiation , Female , Follow-Up Studies , Hematologic Neoplasms/complications , Hematologic Neoplasms/therapy , Humans , Incidence , Male , Middle Aged , Radiotherapy Dosage , Retrospective Studies , Transplantation Conditioning/methods
14.
Tohoku J Exp Med ; 197(1): 35-40, 2002 May.
Article in English | MEDLINE | ID: mdl-12180791

ABSTRACT

Rectum reference dose points have a direct impact on the morbidity seen in gynecological intracavitaty radiotherapy. The aim of this study is to obtain less morbidity by marking rectum with radio opaque solution. Fourteen patients with gynecological cancer who underwent external radiotherapy received 15 Gray (Gy) intracavitary radiotherapy. During the internal radiotherapy planning, radio opaque solution has been administered into the rectum to observe it on lateral radiogram. Thus rectum reference dose point and five points were marked at sites nearest to the sources. Nucletron Planning system was used for obtaining three-dimensional planning. After therapy patients were followed at every three months. Median follow-up was 18 months. Most frequently observed morbidities were grade 1-2 rectitis and cystitis in six patients. As a result, more accurate rectum dose values and less factors causing dose changing can provide better results for gynecological intracavitary brachytherapy.


Subject(s)
Brachytherapy/adverse effects , Brachytherapy/methods , Genital Neoplasms, Female/pathology , Genital Neoplasms, Female/radiotherapy , Rectum/radiation effects , Dose-Response Relationship, Radiation , Female , Follow-Up Studies , Humans , Neoplasm Staging , Palliative Care , Radiation Dosage , Radiation Injuries/prevention & control , Radiotherapy Planning, Computer-Assisted , Reference Standards , Risk Assessment , Sampling Studies , Treatment Outcome
15.
Haematologia (Budap) ; 32(4): 397-403, 2002.
Article in English | MEDLINE | ID: mdl-12803114

ABSTRACT

Mycosis fungoides is the most common form of cutaneous T-cell lymphoma. In our department, between January 1995 to January 2001, we treated eleven patients with mycosis fungoides by total body skin electron irradiation to evaluate its influence. According to our knowledge, our department is the only center in Turkey capable of applying total skin electron beam therapy. Total skin electron beam therapy was applied by using the "translational technique". Daily doses (4 Gray) were given in a total of seven fractions according to the conventional fractionation scheme. There were 6 patients with stage I disease, 3 patients with stage II and 2 patients with stage IV disease. Except stage IV patients, we obtained good cutaneous results. According to our observation, in early stage mycosis fungoides total body skin electron irradiation can provide good cutaneous response, but for stage IV only moderate pallation can be obtained.


Subject(s)
Electrons/therapeutic use , Mycosis Fungoides/radiotherapy , Radiotherapy, High-Energy/methods , Skin Neoplasms/radiotherapy , Aged , Female , Humans , Male , Middle Aged , Mycosis Fungoides/pathology , Neoplasm Staging , Palliative Care , Particle Accelerators , Radiotherapy Dosage , Skin Neoplasms/pathology , Turkey
SELECTION OF CITATIONS
SEARCH DETAIL
...